ReviewTranslational lung cancer research2019
Update on screening for lung cancer.
Review in Translational lung cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Long noncoding RNA MALAT1 as a candidate serological biomarker for the diagnosis of non-small cell lung cancer: A meta-analysis.Thoracic cancer · 2020Pooled it
- Artificial intelligence in thoracic surgery: Perspectives and challenges.Surgery in practice and science · 2025Review
- Olfactory and Gustatory Disturbances as Early Indicators of Lung Cancer in Patients with Sleep Disorders: A Retrospective Cohort Study from the TriNetX US Collaborative Networks.International journal of medical sciences · 2025Article
- Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening.Journal of clinical medicine · 2024Review
- Lung cancer screening: where do we stand?Breathe (Sheffield, England) · 2024Review
- Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study.Journal of clinical medicine · 2023Article
- Evaluation of benefits and harms of adaptive screening schedules for lung cancer: A microsimulation study.Journal of medical screening · 2022Article
- Artificial intelligence assisted display in thoracic surgery: development and possibilities.Journal of thoracic disease · 2021Review
- Robotic-assisted thoracic surgery reduces perioperative complications and achieves a similar long-term survival profile as posterolateral thoracotomy in clinical N2 stage non-small cell lung cancer patients: a multicenter, randomized, controlled trial.Translational lung cancer research · 2021Article
- Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis.Annals of translational medicine · 2021Article
- Lung cancer: progression of heat shock protein 70 in association with flap endonuclease 1 protein.3 Biotech · 2021Article
- Cancer Prevention and Screening for Older Adults: Part 1. Lung, Colorectal, Bladder, and Kidney Cancer.Journal of the American Geriatrics Society · 2020Review
- Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors.Annals of translational medicine · 2020Article
- Clinical characteristics of patients withTranslational cancer research · 2020Article
- Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer.Translational lung cancer research · 2020Article
- Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma.Translational lung cancer research · 2020Article
- Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the leading cause of cancer related death world wide, lung cancer is responsible for an enormous amount of suffering and disability. Detection of disease when it is surgically curable is associated with far greater odds of cure, and therefore it is a disease for which mass screening of high-risk populations has significant potential benefit. Starting in 2011, with the publication of the National Lung Screening Trial from United States (U.S.), mass screening programs have emerged throughout the U.S., as well as in other countries. More recently, large European screening trials have confirmed the potential mortality benefit of lung cancer screening. This invited non-systematic review paper covers the trial that data justify mass-screening, for lung cancer and proposes strategies for maximizing benefits and minimizing harms in the context of a mass public health lung cancer screening program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.